✨ Free AI Report
Pulmonx Corporation: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Pulmonx Corporation
Company Research

Pulmonx Corporation: Business Overview, Financials & Competitive Analysis

Pulmonx Corporation scores 4/10 on the AskCyborg Cyborg Score (Mixed). Pulmonx operates in an attractive niche market (minimally invasive COPD treatment) with strong gross margins but must demonstrate a clear path to profitability while expanding its international presence. Pulmonx stock trades at $3.77 per share with a market capitalization of $150.03M, representing a -90.41% return since its October 2020 IPO.

What is Pulmonx Corporation's industry? Pulmonx Corporation (pulmonx.com) operates in Medical Devices - Respiratory/Pulmonary Care. AskCyborg classifies Pulmonx Corporation under Medical Devices - Respiratory/Pulmonary Care in its company registry.

Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The commercial-stage medical technology company provides a minimally invasive tr...

4/ 10Mixed

Cyborg Score thesis

Pulmonx operates in an attractive niche market (minimally invasive COPD treatment) with strong gross margins but must demonstrate...

Read the full analyst-debate transcript →
Industry Medical Devices - Respiratory/Pulmonary Care
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Pulmonx Corporation Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Pulmonx Corporation

AskCyborg analysts argue the bull and bear cases for Pulmonx Corporation across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Pulmonx Corporation OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Pulmonx Corporation Overview

Pro stress-test →

Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The commercial-stage medical technology company provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease.

Strategic Profile

Pro stress-test →

Pulmonx's Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and treat patients. In Q2 2025, the company achieved total revenue of $23.9 million, representing a 15% year-over-year increase, driven by strong international growth of 32% ($9.1 million), while U.S. revenue grew 6% ($14.7 million).

Competitive Landscape

Pro stress-test →

Pulmonx operates in the minimally invasive COPD treatment space with its flagship Zephyr Endobronchial Valve therapy. The market includes broader lung disease and respiratory device manufacturers, though direct competitors in minimally invasive emphysema treatment are limited. The company competes on clinical efficacy, physician training networks, and geographic market penetration.

Industry Context

Pulmonx Corporation operates in Medical Devices - Respiratory/Pulmonary Care.

Key facts

Founded: 1995 · Headquarters: Redwood City, California, United States · Employees: 291 · Revenue: $23.9M (Q2 2025) · Market cap: $150M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Pulmonx Corporation.

  • Q2 2025 revenue of $23.9M showed 15% YoY growth with international markets expanding faster (32%) than domestic U.S. market (6%)
  • Company maintains healthy 72% gross margin despite significant net losses, indicating product economics are sound but scale is insufficient
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2025New CFO Derrick Sung and other executives granted significant equity awards (1,625,000 shares total) under 2025 Inducement Plan
  • September 2025Management participation in Wells Fargo Healthcare Conference and Lake Street Best Ideas Growth Conference
  • +1 moreTrack every material event for Pulmonx Corporation as it happens. Explore monitoring →
Get alerted when Pulmonx Corporation has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Endobronchial Valve SystemsAlternative minimally invasive approaches to severe emphysema treatment→Lung Volume Reduction SurgeryInvasive alternative to Zephyr Valve therapy for emphysema management→Pulmonary Rehabilitation ProgramsConservative management approach for COPD/emphysema patients→

Compare Pulmonx Corporation with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Pulmonx Corporation operates in Medical Devices - Respiratory/Pulmonary Care. See how the rest of the sector scores on the Cyborg framework.

Browse Medical Devices - Respiratory/Pulmonary Care research →
NEW · MCP server

Ask your AI assistant about Pulmonx Corporation

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Pulmonx Corporation and its top competitor on Cyborg Score”
“What did Pulmonx Corporation do this quarter?”
“Is Pulmonx Corporation a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Pulmonx Corporation do?+
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The commercial-stage medical technology company provides a minimally invasive tr...
What is Pulmonx Corporation's Cyborg Score?+
Pulmonx Corporation has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Pulmonx Corporation's main competitors?+
Named competitors include Endobronchial Valve Systems, Lung Volume Reduction Surgery, Pulmonary Rehabilitation Programs. The full competitive landscape is in the AskCyborg report.
How can I get the full Pulmonx Corporation research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Pulmonx Corporation research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Pulmonx Corporation over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.